Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment

BACKGROUND: Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer (BCR) after radical prostatectomy. OBJECTIVE: To...

Full description

Saved in:
Bibliographic Details
Published in:Eur Urol
Main Authors: Loeb, Stacy, Folkvaljon, Yasin, Robinson, David, Schlomm, Thorsten, Garmo, Hans, Stattin, Pär
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927410/
https://ncbi.nlm.nih.gov/pubmed/26743040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.12.013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items